Scarica l'app Stockscreener
75.54
0.44%
0.33
Dopo l'orario di chiusura:
75.54
Arcellx Inc Borsa (ACLX) Ultime notizie
Geode Capital Management LLC Has $81.43 Million Position in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Risks To Shareholder Returns Are Elevated At These Prices For Arcellx, Inc. (NASDAQ:ACLX) - Simply Wall St
Arcellx (NASDAQ:ACLX) Shares Down 4.6%Here's Why - MarketBeat
Y Intercept Hong Kong Ltd Sells 11,955 Shares of Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Arcellx's SWOT analysis: biotech stock's potential in CAR-T therapy market - Investing.com Australia
Heba Nowyhed - The Business Journals
Lord Abbett & CO. LLC Boosts Stake in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Arcellx, Inc. (NASDAQ:ACLX) Shares Sold by State Street Corp - MarketBeat
Arcellx, Inc. (NASDAQ:ACLX) Short Interest Up 17.5% in November - MarketBeat
ASH 2024: Arcellx publishes positive results for Anito-cel in multiple myeloma - Yahoo Finance
Arcellx, Inc. (NASDAQ:ACLX) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Arcellx's SWOT analysis: biotech stock poised for growth amid challenges By Investing.com - Investing.com Canada
Arcellx's SWOT analysis: biotech stock poised for growth amid challenges - Investing.com India
Safety Stands Out in Arcellx Cell Therapy’s ASH Data, But Don’t Overlook Manufacturing Advantages - MedCity News
Stifel maintains Buy on Arcellx stock post ASH24 data By Investing.com - Investing.com Canada
Stifel maintains Buy on Arcellx stock post ASH24 data - Investing.com
Arcellx (NASDAQ:ACLX) Earns Buy Rating from HC Wainwright - MarketBeat
Gilead/Arcellx’s Anito-Cel’s Differentiated Safety Profile Challenges J&J/Legend’s Carvykti - BioSpace
ASH: Gilead/Arcellx Point To Anito-Cel’s Safety, High-Risk Patient Advantages - Citeline News & Insights
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. - MSN
Arcellx shares remain a Buy at TD Cowen following anito-cell data release - Investing.com
In-Depth Examination Of 14 Analyst Recommendations For Arcellx - Benzinga
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients - AOL
14 Analysts Have This To Say About Arcellx - Inkl
Arcellx shares target lifted, buy rating continued on positive developments By Investing.com - Investing.com Nigeria
Arcellx shares target lifted, buy rating continued on positive developments - Investing.com
Arcellx (NASDAQ:ACLX) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Arcellx, Inc. Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed or Refractory Multiple Myeloma to Be Presented During an Oral Presentation At the 66Th Ash Annual Meeting and Exposition - Marketscreener.com
Arcellx, Gilead announce new data from iMMagine-1 study of anitocabtagene autole - TipRanks
Arcellx's Multiple Myeloma Treatment Shows Breakthrough 97% Response Rate in Phase 2 Trial - StockTitan
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition - Business Wire
Leerink Partnrs Reduces Earnings Estimates for Arcellx - MarketBeat
Jacobs Levy Equity Management Inc. Has $6.68 Million Holdings in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Stake in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Arcellx director Kavita Patel sells $137,817 in stock By Investing.com - Investing.com Canada
Arcellx director Kavita Patel sells $137,817 in stock - Investing.com
Arcellx, Inc. (NASDAQ:ACLX) is Samsara BioCapital LLC's 6th Largest Position - MarketBeat
RA Capital Management L.P. Acquires 247,465 Shares of Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Citigroup Inc. Purchases 21,262 Shares of Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
The Manufacturers Life Insurance Company Increases Position in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Parkman Healthcare Partners LLC Sells 90,351 Shares of Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Janus Henderson Group PLC Has $168.03 Million Position in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Erste Asset Management GmbH Takes Position in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
(ACLX) Trading Signals - Stock Traders Daily
Arcellx, Inc. (NASDAQ:ACLX) Short Interest Update - MarketBeat
Arcellx price target raised to $115 from $73 at Barclays - MSN
Intech Investment Management LLC Acquires Shares of 9,579 Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Suvretta Capital Management LLC Sells 826,304 Shares of Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Fmr LLC Has $541.08 Million Holdings in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Acuta Capital Partners LLC Has $5.19 Million Position in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
FORA Capital LLC Purchases Shares of 12,935 Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):